HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

DDMS

a water soluble and highly specific inhibitor of cytochrome P-450 omega-hydroxylase
Also Known As:
N-methylsulfonyl-12,12-dibromododec-11-enamide
Networked: 17 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Gross, Garrett J: 3 articles (02/2006 - 10/2004)
2. Falck, John R: 3 articles (02/2006 - 10/2004)
3. Campbell, William B: 3 articles (02/2006 - 10/2004)
4. Nithipatikom, Kasem: 3 articles (02/2006 - 10/2004)
5. Endsley, Michael P: 2 articles (02/2006 - 10/2004)
6. Moore, Jeannine M: 2 articles (02/2006 - 10/2004)
7. Isbell, Marilyn A: 2 articles (02/2006 - 10/2004)
8. Gross, Eric R: 2 articles (12/2004 - 10/2004)
9. Khan, Ashfa A: 1 article (10/2015)
10. Sultan, Tipu: 1 article (10/2015)

Related Diseases

1. Ischemia
12/01/2004 - "Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. "
10/31/2008 - "Groups received either 17-octadecynoic acid (17-ODYA, 0.3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, 0.4 or 0.8 mg/kg), N-hydroxy-N'-(4-butyl-2-methylphenyl) formamidine (HET0016, 0.1 or 1 mg/kg) or vehicle 10 min prior to ischemia. "
12/01/2004 - "Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP omega-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP omega-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. "
02/01/2006 - "In this study, we demonstrated that a specific CYP omega-hydroxylase inhibitor, N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), markedly reduced 20-HETE production during ischemia-reperfusion and reduced myocardial infarct size compared with control [19.5 +/- 1.0% (control), 9.6 +/- 1.5% (0.40 mg/kg DDMS), 4.0 +/- 2.0% (0.81 mg/kg DDMS), P < 0.01]. "
10/15/2004 - "A nonspecific CYP inhibitor, miconazole, and 2 specific CYPomega-hydroxylase inhibitors, 17-octadecanoic acid (17-ODYA) and N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), markedly inhibited 20-HETE production during ischemia-reperfusion and produced a profound reduction in myocardial infarct size (expressed as a percent of the area at risk) (19.6+/-1.7% [control], 8.4+/-2.5% [0.96 mg/kg miconazole], 5.9+/-2.2% [0.28 mg/kg 17-ODYA], and 10.8+/-1.8% [0.40 mg/kg DDMS], P<0.05, respectively). "
2. Myocardial Infarction
3. Reperfusion Injury
4. Retinal Perforations
5. Paresis (Hemiparesis)

Related Drugs and Biologics

1. DDMS
2. cytochrome P-450 omega-hydroxylase
3. 20-hydroxy-5,8,11,14-eicosatetraenoic acid
4. Diamond
5. Retinaldehyde (Retinal)
6. Miconazole (Monistat)
7. 17-octadecynoic acid
8. Insulin (Novolin)
9. Hydroxyeicosatetraenoic Acids (HETE)
10. N- methylsulfonyl- 6- (2- propargyloxyphenyl)hexanamide

Related Therapies and Procedures

1. Vagus Nerve Stimulation
2. Vitrectomy